Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in THP-1 and Jurkat cells

Keyphrases

• Angiogenic 7%
• Annexin V 7%
• Anti-inflammatory Effect 7%
• Antiproliferative Activity 100%
• Apoptotic Effect 100%
• Caspase-3 Activity 14%
• Cell Proliferation 14%
• Chemokines 7%
• Clinical Benefit 7%
• Combined Activity 7%
• Cytokine Release 7%
• Cytokine Secretion 14%
• Cytotoxic Drugs 7%
• Cytotoxic Effect 7%
• Cytotoxicity 7%
• Dose Effect 14%
• Enhanced Release 7%
• Enzyme Activity 7%
• Etoposide 100%
• Eukaryotic Cells 7%
• Fluoroquinolones 14%
• Fold Increase 7%
• Induced Apoptosis 14%
• Inflammatory Cytokines 14%
• Inflammatory Effects 100%
• Interleukin-1β 7%
• Interleukin-8 28%
• Jurkat Cells 100%
• Moxifloxacin 100%
• Proliferation Apoptosis 7%
• Sparing Effect 7%
• THP-1 Cells 100%
• Topoisomerase II 21%
• Topoisomerase Inhibitors 7%
• Tumor 7%
• Tumor Cells 7%
• VP16 100%

Immunology and Microbiology

• Antiinflammatory Activity 33%
• Caspase 66%
• Cell Proliferation 66%
• Chemokine 33%
• Cytokine Release 100%
• Cytotoxicity 66%
• Enzyme Activity 33%
• Eukaryotic Cell 33%
• Interleukin-1 33%
• Low Drug Dose 33%
• Proinflammatory Cytokine 66%
• Tumor Cell 33%
• Tumor Necrosis Factor 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Antiinfective Agent 11%
• Antiinflammatory Activity 11%
• Caspase 3 22%
• Chemokine 11%
• Cytokine 33%
• Cytotoxic Agent 11%
• Cytotoxicity 11%
• DNA Topoisomerase (ATP Hydrolysing) 33%
• Etoposide 100%
• Gyrase Inhibitor 11%
• Lipocortin 5 11%
• Moxifloxacin 100%
• Neoplasm 22%
• Quinolone Derivative 22%
• Tumor Necrosis Factor 11%